Provided by Tiger Trade Technology Pte. Ltd.

Aptevo Therapeutics

7.32
-0.0300-0.41%
Post-market: 7.350.0306+0.42%19:04 EST
Volume:11.28K
Turnover:82.02K
Market Cap:7.30M
PE:-0.02
High:7.42
Open:7.11
Low:7.11
Close:7.35
52wk High:1,439.96
52wk Low:5.94
Shares:997.80K
Float Shares:750.50K
Volume Ratio:0.54
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-351.3949
EPS(LYR):-1,747.6642
ROE:-242.74%
ROA:-79.19%
PB:0.42
PE(LYR):0.00

Loading ...

Aptevo Therapeutics management to meet virtually with Roth Capital

TIPRANKS
·
Nov 07, 2025

Aptevo Therapeutics reports Q3 EPS (23c) vs. ($357.86) last year

TIPRANKS
·
Nov 06, 2025

Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate

Benzinga
·
Nov 06, 2025

Aptevo Therapeutics reports third-quarter net loss of $7.5 million

Reuters
·
Nov 06, 2025

Aptevo Therapeutics Q3 Operating Income USD -7.61 Million

THOMSON REUTERS
·
Nov 06, 2025

Aptevo Therapeutics Q3 EPS USD -2.23

THOMSON REUTERS
·
Nov 06, 2025

Aptevo Therapeutics Inc expected to post a loss of $2.09 a share - Earnings Preview

Reuters
·
Nov 03, 2025

Aptevo Therapeutics announces interim results for mipletamig in frontline AML from ongoing RAINIER clinical trial

Reuters
·
Oct 08, 2025

Aptevo Therapeutics Files Initial Beneficial Ownership Statement for Bank of America Corp

Reuters
·
Oct 04, 2025

Aptevo Therapeutics files to sell 6.9M shares of common stock for holders

TIPRANKS
·
Oct 02, 2025

Gold Falls Over 1%; Darden Posts Downbeat Earnings

Benzinga
·
Sep 19, 2025

Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds

MT Newswires Live
·
Sep 18, 2025

Why Is Aptevo Therapeutics Stock (APVO) Up 85% Today?

TIPRANKS
·
Sep 18, 2025

Aptevo Therapeutics Shares Jump 60% to $2.3 Premarket After Steven Cohen Reports 9.1% Passive Stake in Co

THOMSON REUTERS
·
Sep 18, 2025

Aptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results

Benzinga
·
Sep 18, 2025

Steven Cohen Reports 9.1% Passive Stake in Aptevo Therapeutics Inc as of September 16 - SEC Filing

THOMSON REUTERS
·
Sep 18, 2025

Aptevo Therapeutics Shares Rise 35% After Co's Blood Cancer Therapy Shows 100% Remission in Trial

THOMSON REUTERS
·
Sep 16, 2025

Aptevo Therapeutics Says Mipletamig For AML Treatment Delivers 100% Remission Rate in Phase 1b/2 Study; Shares Up Pre-Bell

MT Newswires Live
·
Sep 16, 2025

Aptevo says mipletamig deliver 100% remission rate in RAINIER cohort 3

TIPRANKS
·
Sep 16, 2025

Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451

Reuters
·
Sep 04, 2025